drugset / Trial / NCT01555853
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with recurrent or refractory Hodgkin or B-cell non-Hodgkin lymphoma. More effective and well tolerated therapies are needed to treat patients with relapsed and refractory lymphomas. Nab-paclitaxel combines a chemotherapeutic agent with a protein which may increase the anticancer drug concentration in the tumor while reducing toxic effects in normal tissue and may be an effective treatment for lymphoma.
Timeline
- Start
- 2012-07
- Primary completion
- 2016-06
- Completion
- 2016-06
Outcome
Outcome not reported
Stopped (Enrollment): “completed accrual to phase I but drug did not show activity, so halted before initiation of phase II”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 150 mg/m2 | Intravenous |